A phase II trial suggested that CXCR4 inhibition combined with pembrolizumab can reduce populations of immunosuppressive cells in the tumor microenvironment of patients with chemotherapy-resistant advanced pancreatic cancer [104]. The gene discussed is CXCR4; the disease is familial pancreatic carcinoma.